DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

Information source: Amgen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura

Intervention: Romiplostim (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: Amgen

Official(s) and/or principal investigator(s):
MD, Study Director, Affiliation: Amgen

Summary

This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week. Dose adjustment will be based on platelet counts, and will be allowed throughout the duration of the study. Rescue therapies are allowed at any time during the study. Reductions in concurrent ITP therapies may occur at any time when platelet counts are > 50,000.

Clinical Details

Official title: An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Adverse Events

Secondary outcome:

Platelet Response (Definition 1)

Platelet Response (Definition 2)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subject is ≥ 18 years of age

- Subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the

American Society of Hematology guidelines

- If Subject is > 60 years of age, subject has a written bone marrow aspiration and/or

biopsy report consistent with a diagnosis of ITP

- Subject has received at least 1 prior therapy for ITP

- Subject's platelet count is ≤ 30,000 or the subject is experiencing bleeding that is

uncontrolled with conventional therapies

- Subject (or legally-acceptable representative) is willing and able to provide written

informed consent Exclusion Criteria:

- Subject has a history of hematological malignancy, myeloproliferative disorder,

myelodysplastic syndrome (MDS), or bone marrow stem cell disorder

- Subject has participated in any study evaluating PEG-rHuMGDF, recombinant human

thrombopoietin (rHuTPO), or related platelet product

- Subject has a known hypersensitivity to any recombinant E coli-derived product

- Subject has received any therapeutic drug or device that is not approved by the local

regulatory health agency for any indication within 4 weeks of Screening

- Subject is of reproductive potential and is not using adequate contraceptive

precautions, in the judgment of the investigator

- Subject is pregnant or breast feeding

- Investigator has concerns regarding the subject's ability to comply with the protocol

procedures

Locations and Contacts

Additional Information

AmgenTrials clinical trials website

Starting date: February 2005
Last updated: January 11, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017